[{"notes_id":"1_166","category":"6","subcategory":"2","title":"Osteoporosis: management","body":"The National Osteoporosis Guideline Group (NOGG) updated their guidelines in 2021. NICE guidelines also have a section on the management of osteoporosis, largely based on the NOGG guidelines. Remember that osteporosis is usually asymptomatic until a fracture occurs. When thinking about osteoporosis management it is useful to think about a number of potential clinical scenarios:<br \/><ul><li>a patient who has been identified as being at high risk of a fragility fracture based on a QFracture or FRAX score (please see the textbook entry on 'Osteoporosis: assessing risk')<\/li><li>a patient who is about to start treatment that puts them at significant risk of developing osteoporosis - the most common example is longer-term glucocorticoids<\/li><li>a patient who has just had a fragility fracture e.g. a symptomatic osteoporotic vertebral fracture<\/li><\/ul><br \/><h5 class='notes-heading'>General management points<\/h5><br \/>General points about the management of all patients<br \/><ul><li>all patients who are at risk of osteoporosis or have osteoporosis should be given advice regarding:<ul><li>lifestyle changes: a healthy, balanced diet, moderation of alcohol consumption and avoidance of smoking<\/li><li>a sufficient dietary calcium and vitamin D intake:  supplementation should be offered to all women unless the clinician is confident they have adequate calcium intake and are vitamin D replete<\/li><li>encourage a combination of regular weight-bearing and muscle strengthening exercise<\/li><\/ul><\/li><li>secondary causes of osteoporosis should be considered and treated<ul><li>e.g. hypogonadism in women or men e.g. hormone replacement therapy for premature menopause<\/li><\/ul><\/li><li>bisphosphonates are the first-line drug treatment for patients at risk of fragility fractures<ul><li>oral bisphosphonates such as alendronate and risedronate are typically first-line. These are often taken weekly are need taking in a particular way to minimise the risk of oesophageal side-effects<\/li><li>however, the NOGG recommend IV zoledronate as the first-line treatment following a hip fracture. This is given yearly<\/li><\/ul><\/li><li>denosumab is generally used as a second-line treatment<\/li><li>other possible treatment options include: <ul><li>strontium ranelate<\/li><li>raloxifene<\/li><li>teriparatide<\/li><li>romosozumab<\/li><\/ul><\/li><\/ul><br \/><h5 class='notes-heading'>Clinical scenarios<\/h5><br \/>Fragility risk fracture assessment<br \/><ul><li><span class=\"concept\" data-cid=\"12227\">if a patient is deemed high-risk based on a QFracture or FRAX score they should have a DEXA scan to assess bone mineral density (BMD)<\/span><ul><li>the BMD threshold for defining osteoporosis is a T-score of - 2.5 SD or below<\/li><li>some patients may not be suitable for BMD assessment due to frailty etc.<\/li><\/ul><\/li><li>general osteoporosis management as above<\/li><li>oral bisphosphonates are used first-line e.g. alendronate or risedronate<\/li><\/ul><br \/>Postmenopausal women, and men age \u226550, who are treated with oral glucocorticoids:<br \/><ul><li>if starting \u22657.5 mg\/day prednisolone or equivalent for the next 3 months, start bone protective treatment at the same time <\/li><li>general osteoporosis management as above<\/li><li><span class=\"concept\" data-cid=\"12228\">don't wait for a DEXA scan before starting treatment<\/span><\/li><li>oral bisphosphonates are used first-line e.g. alendronate or risedronate<\/li><\/ul><br \/>A <span class=\"concept\" data-cid=\"12229\">postmenopausal woman, or a man age \u226550 has a symptomatic osteoporotic vertebral fracture<\/span>:<br \/><ul><li>general osteoporosis management as above<\/li><li>start treatment straight away - oral bisphosphonates are used first-line e.g. alendronate or risedronate<\/li><\/ul><br \/>Hip fracture in older adults<br \/><ul><li>in <span class=\"concept\" data-cid=\"12229\">older adults a hip fracture is a manifestation of osteoporosis<\/span><ul><li><span class=\"concept\" data-cid=\"11815\">following a fragility fracture in women \u2265 75 years, a DEXA scan is not necessary to diagnose osteoporosis and hence commence a bisphosphonate<\/span><\/li><li>BMD should be measured, but this acts as a baseline rather than determining whether treatment should be given<\/li><\/ul><\/li><li>bisphosphonates should be given first-line<ul><li>NOGG recommends IV zoledronate but local guidelines may vary and oral bisphosphonates are often used<\/li><\/ul><\/li><\/ul><br \/><h5 class='notes-heading'>Follow-up<\/h5><br \/>Plan to prescribe <span class=\"concept\" data-cid=\"7877\">oral bisphosphonates for at least 5 years<\/span>, or intravenous bisphosphonates for at least 3 years and then re-assess fracture risk.<br \/><br \/><h5 class='notes-heading'>Supplementary notes on treatment<\/h5><br \/>Bisphosphonates<br \/><ul><li>bisphosphonates bind to hydroxyapatite in bone, inhibiting osteoclast-mediated bone resorption<\/li><li>common side effects include gastrointestinal discomfort, oesophagitis, and hypocalcaemia. Atypical femoral fractures and osteonecrosis of the jaw are rare but serious risks.<\/li><li>available in oral and intravenous formulations. Oral bisphosphonates should be taken with a full glass of water, on an empty stomach, and the patient should remain upright for at least 30 minutes afterwards.<\/li><\/ul><br \/>Denosumab<br \/><ul><li>human monoclonal antibody that inhibits RANK ligand, which in turn inhibits the maturation of osteoclasts<\/li><li>also used for cancer patients with bone metastases to reduce skeletal-related events.<\/li><li>given as a single subcutaneous injection every 6 months<\/li><\/ul><br \/>Raloxifene <br \/><ul><li>selective oestrogen receptor modulator (SERM)<\/li><li>has been shown to prevent bone loss and to reduce the risk of vertebral fractures, but has not yet been shown to reduce the risk of non-vertebral fractures<\/li><li>has been shown to increase bone density in the spine and proximal femur<\/li><li>may worsen menopausal symptoms<\/li><li>increased risk of thromboembolic events<\/li><li>may decrease the risk of breast cancer<\/li><\/ul><br \/>Strontium ranelate <br \/><ul><li>'dual action bone agent' - increases deposition of new bone by osteoblasts (promotes differentiation of pre-osteoblast to osteoblast) and reduces the resorption of bone by inhibiting osteoclasts<\/li><li>concerns regarding the safety profile of strontium have been raised recently. It should only be prescribed by a specialist in secondary care<\/li><li>due to these concerns the European Medicines Agency in 2014 said it should only be used by people for whom there are no other treatments for osteoporosis<\/li><li>increased risk of cardiovascular events: any history of cardiovascular disease or significant risk of cardiovascular disease is a contraindication<\/li><li>increased risk of thromboembolic events: a Drug Safety Update in 2012 recommended it is not used in patients with a history of venous thromboembolism<\/li><li>may cause serious skin reactions such as Stevens Johnson syndrome<\/li><\/ul><br \/>Teriparatide<br \/><ul><li>recombinant form of parathyroid hormone<\/li><li>very effective at increasing bone mineral density but role in the management of osteoporosis yet to be clearly defined<\/li><\/ul><br \/>Romosozumab<br \/><ul><li>a monoclonal antibody that inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption<\/li><li>this dual action significantly improves bone density and reduces fracture risk.<\/li><\/ul><br \/><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/xrb167b.jpg'><img class='ajaximage' src='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/xrb167.jpg'\/><\/a><\/td><\/tr><tr><td valign='top' align='left'><span style = 'font-size:11px; color:LightGray;'>&copy; Image used on license from <\/span><a href='http:\/\/www.radiopaedia.org\/'  target='_blank' style = 'font-size:11px; color:LightGray;' >Radiopaedia<\/a><\/td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/xrb167b.jpg'><img src='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/css\/images\/mag_glass.png'\/><\/a><\/td><\/tr><\/table><\/CENTER><div class='imagetext'>MRI showing osteoporotic fractures of the 10th and 12th thoracic vertebrae.<\/div>","notes_hash":"faf778f243e7726ef987b68f270f3f91","knowledge_graph_node_id_link":10843,"links":"<table style='width:100%'><tr><td>The National Osteoporosis Guideline Group<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1421\" data-linkid=\"1421\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1421\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">10<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1421\" data-linkid=\"1421\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1421\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">12<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nogg.org.uk\/sites\/nogg\/download\/NOGG-Guideline-2021-g.pdf\">2021 Clinical guideline for the prevention and treatment of osteoporosis<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_874\" data-linkid=\"874\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_874\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">11<\/span><button type=\"button\" style=\"\" id=\"link_dislike_874\" data-linkid=\"874\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_874\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">9<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/TA161\/chapter\/1-guidance\">2008 Osteoporosis: secondary prevention<\/a><\/td><\/tr><\/table>","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/DBZIBFC8ang\" data-description=\"Osteoporosis pharmacology, prevention and treatment\" data-upvotes=\"1\" data-downvotes=\"3\" data-media=\"1279\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/DBZIBFC8ang\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/DBZIBFC8ang\" data-description=\"Osteoporosis pharmacology, prevention and treatment\" data-upvotes=\"1\" data-downvotes=\"3\" data-media=\"1279\">Osteoporosis pharmacology, prevention and treatment<\/a><\/td><\/tr><tr><td><span ><small>Armando Hasudungan - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2260\" data-mediaid=\"2260\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_2260\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">1<\/span><button type=\"button\" style=\"\" id=\"media_dislike_2260\" data-mediaid=\"2260\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_2260\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">3<\/span><\/td><\/tr><\/table>","concepts_for_notes":[],"category_name":"Musculoskeletal","subcategory_name":"Rheumatology","comment_count":7},"",[]]